Cytogen, Berlex deal

Berlex received an exclusive license to manufacture and sell in North and South America CYTO's Quadramet samarium 153 lexidronam injection to treat pain associated with cancer that has spread to the bone. Berlex will make an $8 million upfront payment to CYTO, of which $4 million will be paid to DuPont Merck Pharmaceutical Co. (Wilmington, Del.) to secure manufacturing rights. In June, CYTO and DuPont Merck terminated their 1994 marketing agreement for the product, but DuPont Merck retained a two-year manufacturing contract with CYTO (see BioCentury, June 15). ...